Carte­sian re­veals long-term mid-stage da­ta for cell ther­a­py in myas­the­nia gravis

Carte­sian Ther­a­peu­tics said its au­tol­o­gous CAR-T ther­a­py has shown “sus­tained ben­e­fits” in peo­ple with a rare au­toim­mune dis­ease, ac­cord­ing to the lat­est da­ta cut from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER